About Varda Space Industries
Varda Space Industries was founded in 2020 by Will Bruey, Delian Asparouhov, and Eric Lasker, pursuing the ambitious goal of manufacturing certain pharmaceutical compounds and other advanced materials in the microgravity environment of space, based on scientific research suggesting that certain manufacturing processes, particularly the crystallization of some pharmaceutical compounds, can produce meaningfully different and, in some cases, more effective or purer crystal structures when performed in microgravity conditions compared to manufacturing under Earth's normal gravity, a phenomenon that had been studied to some degree on the International Space Station and other prior microgravity research platforms but had never been commercially exploited at meaningful production scale given the enormous historical cost and complexity of accessing space for any purpose.
Varda's approach involves launching small, uncrewed orbital capsules containing manufacturing equipment into low Earth orbit, where the capsule spends a period of time conducting its manufacturing process, such as pharmaceutical crystallization, in the microgravity environment, before the capsule autonomously reenters Earth's atmosphere and lands, typically in a remote desert location, allowing the manufactured product to be recovered and analyzed or further processed for potential pharmaceutical or other commercial use, an approach that takes advantage of the dramatically reduced launch costs achieved by companies like SpaceX in recent years, which have made the economics of dedicated small-scale space manufacturing missions newly plausible in a way that would have been prohibitively expensive using the launch costs and infrastructure available even one or two decades earlier. The company achieved a significant milestone with its first mission, successfully manufacturing pharmaceutical material in orbit and safely reentering and recovering its capsule, demonstrating the core technical viability of its space-based manufacturing concept, though the company continues working to prove out the commercial economics and scalability of this approach for genuinely commercially viable pharmaceutical and materials production at meaningful volume. Varda has built relationships with pharmaceutical industry partners interested in exploring the potential benefits of microgravity-manufactured pharmaceutical compounds. The company has raised substantial venture funding from investors including Founders Fund, Khosla Ventures, and General Catalyst, reaching a valuation exceeding $1.8 billion, positioning itself among the more distinctive and technically ambitious companies within the broader commercial space industry.
